Gene therapies for rare eye diseases

A fight against blindness!

Press releases

Variant confirme sa percée dans le traitement des rétinopathies héréditaires dépendantes du CRX avec VAR002, un produit innovant de thérapie génique

Mar 30, 2021

VAR002 est protégé par une demande de brevet international qui revendique ce produit innovant de thérapie génique dans ses applications thérapeutiques jusqu’en 2040, principalement pour les dystrophies rétiniennes héréditaires dominantes autosomiques associées à des mutations dans le facteur de transcription CRX. Paris, France, le 30 mars 2021. – Variant, une société dédiée au développement de…

Variant Confirms Breakthrough in Treatment of Hereditary CRX-Dependent Retinopathies with an Innovative Gene Therapy Product VAR002

Mar 16, 2021

VAR002 is protected by an international patent application which claims this innovative product of gene therapy in its therapeutic applications until 2040, primarily for autosomal dominant inherited retinal dystrophies associated with mutations in the CRX transcription factor. Paris, France, March 30, 2021, 6 p.m. – Variant, a company dedicated to developing innovative treatments for inherited…

Denis-CAYET-Tedx

Denis CAYET
CEO

apos1

In 2017, VARIANT initiated a collaborative network with various academic teams in the aim of developing diverse gene therapy approaches for treating CRX-associated retinopathies. The consortium is using complementary disease models to generate robust proofs-of-concept of therapeutic efficiency

apos2

The scientific team

logovariant

Alejandro ESTRADA

Project manager

Elodie-Kim GRELLIER
Effectivness measurmeents

Krishna DAMODAR
Sophie LOURDEL
Joffrey ALVES

 

imagine-logo

Jean-Michel ROZET

Scientific director of genetic
in ophthalmology

Group leader & principal investigator for
"CRX expression variability"

retina-france-logo

Jérome ROGER

CERTO Researcher

Group leader & principal investigator for
“CRX Over-expression”

uca-logo

Thomas LAMONERIE

IBV Unit director

Group leader & principal investigator for
"Allele-specific inhibition” 

 

inmlogo

Vasiliki KALATZIS

INM Vision team leader

Group leader & principal investigator for
"characterisation of patient derived retinal organoids
+ effactiveness measurement”

Products

  • VAR001

    Strategy: Inhibition siRNA gene therapy.
    Administration: Subretinal injection. 
    Therapeutics: Mutation-specific CRX-associated retinopathies.

  • VAR002

    Strategy: Augmentation AAV gene therapy.
    Administration: Subretinal injection. 
    Therapeutics: CRX-associated retinopathies and other hypomorphic gene retinopathies Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), Cone-Rod Dystrophy (CoRD) and neuroprotection of other RPS.

  • VAR003

    Strategy: Inhibition ASO gene therapy.
    Administration: Intravitreal injection.
    Therakpeutics: CRX-associated retinopathies: Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), and Cone-Rod Dystrophy (CoRD).

Denis-CAYET-Tedx

Denis CAYET
CEO

apos1

VARIANT's proof-of-concept studies are particularly innovative. Our therapeutic strategies and drug administration methods make our product portfolio highly attractive to our future partners

apos2

Contact us